GlassScriptPhysician profile
Joseph A Stauber
NPI 1548609779
$37,272.63
in general payments reported to CMS, 2019-2025
54 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,060 · 2020: $2,534 · 2021: $3,949 · 2022: $4,470 · 2023: $4,901 · 2024: $4,699 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,600 · Consulting Fee: $1,800 · Travel and Lodging: $473 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,119.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,600.00 |
| Consulting Fee | $1,800.00 |
| Travel and Lodging | $472.98 |
| Education | $267.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $11,734.82 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Janssen Biotech, INC. | $5,308.70 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $3,834.92 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $2,493.11 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $2,159.91 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,082.03 | 2019-2025 | |
| Lilly USA, LLC | $1,329.80 | 2019-2025 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $993.40 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $904.49 | 2019-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $702.47 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.86 | 2022-2025 | Ofev, Cyltezo |
| Celgene Corporation | $465.56 | 2019 | |
| Horizon Therapeutics Plc | $446.00 | 2019-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $375.69 | 2020-2025 | Strensiq |
| Genzyme Corporation | $363.76 | 2019-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $363.66 | 2021-2022 | |
| Organon LLC | $349.35 | 2021-2025 | Hadlima, Renflexis, Nexplanon |
| Sobi, INC | $314.40 | 2022-2024 | |
| Radius Health, INC. | $273.66 | 2023-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $264.29 | 2021-2024 | Lupkynis |
| Teva Pharmaceuticals USA, INC. | $227.62 | 2021-2024 | Truxima |
| Mallinckrodt Hospital Products INC. | $196.58 | 2020-2025 | Acthar |
| Genentech USA, INC. | $191.37 | 2019-2025 | Actemra |
| Fresenius Kabi USA, LLC | $121.04 | 2023-2025 | Idacio, Tyenne |
| Grifols USA, LLC | $109.84 | 2023-2025 | Xembify, Gamunex-C |
| Medexus Pharma, INC. | $98.58 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $92.85 | 2024 | Arcalyst |
| Sandoz INC. | $87.32 | 2023-2025 | Hyrimoz |
| Sanofi-Aventis U.S. LLC | $78.37 | 2019-2020 | |
| Tersera Therapeutics LLC | $76.63 | 2019-2025 | Quzyttir |
| Hospira, INC. | $75.75 | 2024-2025 | |
| Pacira Therapeutics, INC. | $70.71 | 2019-2021 | |
| Octapharma USA, INC. | $62.64 | 2022-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Kiniksa Pharmaceuticals, LTD. | $57.33 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $55.35 | 2019-2021 | |
| Antares Pharma, INC. | $47.53 | 2019 | |
| Mylan Institutional INC. | $38.61 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $36.59 | 2021 | |
| Kyowa Kirin, INC. | $33.00 | 2024 | Crysvita |
| Mallinckrodt Enterprises LLC | $31.67 | 2019 | |
| Hikma Pharmaceuticals USA | $31.00 | 2019-2020 | |
| Orthogenrx INC. | $23.47 | 2019 | |
| Pharmacosmos Therapeutics INC. | $23.18 | 2022 | |
| Zyla Life Sciences, INC. | $22.68 | 2019 | |
| Sebela Pharmaceuticals INC. | $18.19 | 2019 | |
| Celltrion USA INC. | $17.46 | 2023 | Yuflyma |
| Actelion Pharmaceuticals US, INC. | $16.73 | 2022 | |
| Ani Pharmaceuticals, INC. | $16.13 | 2024 | Purified Cortrophin Gel |
| Tonix Medicines, INC. | $15.47 | 2025 | Tonmya |
| Invivyd INC | $14.47 | 2025 | Pemgarda |
| Depuy Synthes Sales INC. | $13.47 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $12.94 | 2021 | |
| Fidia Pharma USA INC. | $11.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,281.29 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Stauber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.